Mechanisms of Disease: astrocytes in neurodegenerative disease

@article{Maragakis2006MechanismsOD,
  title={Mechanisms of Disease: astrocytes in neurodegenerative disease},
  author={Nicholas J. Maragakis and Jeffrey D. Rothstein},
  journal={Nature Clinical Practice Neurology},
  year={2006},
  volume={2},
  pages={679-689}
}
The term neurodegenerative disease refers to the principal pathology associated with disorders such as amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease, and it is presumed that neurodegeneration results in the clinical findings seen in patients with these diseases. Decades of pathological and physiological studies have focused on neuronal abnormalities in these disorders, but it is becoming increasingly evident that astrocytes are also important… 
View on Springer
direct-ms.org
758 Citations
Highly Influential Citations
34
Background Citations
325
Methods Citations
2
Results Citations
5

758 Citations

Citation Type

Citation Type

The Role of Astrocytes in Parkinson’s Disease
TLDR
Combined data suggest that protoplasmic astrocytes lose their protective function in patients with Parkinson’s disease, leaving neurons vulnerable to perturbations and insults they would normally be protected from.
Neuron-Astrocyte Interactions in Parkinson’s Disease
TLDR
This review highlights neuron-astrocyte interaction as a target for the development of disease-modifying drugs for PD in the future and discusses therapeutic strategies for the prevention of dopaminergic neurodegeneration.
Reactive Astrocytes as Drug Target in Alzheimer's Disease
TLDR
In this review, recent insights on the involvement of, tonic inhibition, astrocytic glutamate transporters and aquaporin in the pathogenesis of Alzheimer's disease are provided.
Targeting Glial Cells to Elucidate the Pathogenesis of Huntington’s Disease
TLDR
The importance of glial cells and inflammation in HD pathogenesis is focused on and potential anti-inflammatory interventions for HD are discussed.
Inflammation in Parkinson's disease.
Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease.
TLDR
The main purpose of this review is to provide a comprehensive insight into the role of astrocytes in the neuroinflammatory pathogenesis of AD and to attenuating neuroinflammation in the early stage of AD.
Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis
TLDR
The mechanisms of action of astrocytes, microglia, and T-lymphocytes in the nervous system in health and during the pathogenesis of ALS are reviewed and the therapeutic potential of these cellular populations, after transplantation into ALS patients and animal models of the disease, in modulating the environment surrounding motor neurons from pro-inflammatory to neuroprotective is evaluated.
Phenotypic heterogeneity of astrocytes in motor neuron disease
TLDR
The evidence showing that astrocytes are playing profound roles in the disease process of amyotrophic lateral sclerosis is summarized and phenotypic and functional diversity of these cells will become more attractive therapeutic targets for neurological diseases are summarized.
The contribution of astrocytes to Alzheimer's disease.
TLDR
Current evidence on the multi-faceted functions of astrocytes in AD is summarized, highlighting the significant scope available for future therapeutic targets.
Metabolic disturbances in diseases with neurological involvement.
TLDR
Some metabolic alterations related to the pathophysiology of diseases with neurological involvement and aging process may help identifying early disease biomarkers and lead to more effective therapies to improve the quality of life of the patients affected by these devastating illnesses.
...
...

References

SHOWING 1-10 OF 82 REFERENCES
Cellular pathology of Parkinson’s disease: astrocytes, microglia and inflammation
TLDR
The different aspects of activated glial cells and potential mechanisms that mediate or protect against cell loss in PD are discussed.
Impaired Glutamate Transport in a Mouse Model of Tau Pathology in Astrocytes
TLDR
A transgenic mouse model of tau pathology in astrocytes is generated by expressing the human tau protein under the control of the glial fibrillary acidic protein (GFAP) promoter and it is demonstrated that compromised motor function and deficits in neuromuscular strength are observed that correlates with reduced expression of glutamate transporter-1 and occurs concurrent with tau inclusion pathology.
Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic Mice
TLDR
It is shown that a decreased mRNA level of the major astroglial glutamate transporter (GLT1) in the striatum and cortex of these mice is accompanied by a concomitant decrease in glutamate uptake, suggesting that a defect in astrocytic glutamate uptake may contribute to the phenotype and neuronal cell death in HD.
Widespread cytoskeletal pathology characterizes corticobasal degeneration.
TLDR
It is demonstrated that the nonamyloid cortical plaques of CBD are actually collections of abnormal tau in the distal processes of astrocytes, which refines the diagnosis and pathophysiological understanding of this unique disease and has important implications for other neurodegenerative diseases, like Alzheimer's disease.
Aberrant RNA Processing in a Neurodegenerative Disease: the Cause for Absent EAAT2, a Glutamate Transporter, in Amyotrophic Lateral Sclerosis
Chapter 36: Astrocytes and Parkinson's disease
Transgenic Mouse Model of Tau Pathology in Astrocytes Leading to Nervous System Degeneration
TLDR
The transgenic Tg mice recapitulate key features of astrocytic pathology observed in human tauopathies and demonstrate functional consequences of this pathology including neuron degeneration in the absence of neuronal tau inclusions.
Glutamate transporters: animal models to neurologic disease
Amyotrophic Lateral Sclerosis: Pathogenesis, Differential Diagnoses, And Potential Interventions
TLDR
Findings are inconclusive, and further investigations are underway, but at present, nonpharmacologic interventions such as nutritional support; physical, speech, and occupational therapy; and respiratory management offer the best means of improving quality of life for patients with ALS.
Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis.
TLDR
ALS is associated with a defect in high-affinity glutamate transport that has disease, region, and chemical specificity and could lead to neurotoxic levels of extracellular glutamate and thus be pathogenic in ALS.
...
...